title: Financial aspects of haemophilia care in Puerto Rico and other Latin American countries.
abstract: The present cost of optimal care in haemophilia is very high. The paradigm of comprehensive care approach, including the essential elements of continuous integrated multidisciplinary health services and the provision of home care with early use of antihaemophilic products requires abundant economic resources that usually are not readily available in nonaffluent countries. A cost-effective comprehensive paediatric haemophilia programme has been operating in Puerto Rico during the last 15 years that provides quality care to over 90% of paediatric haemophiliacs, and is financed mainly by the local government health system. Efforts are also being made to provide and/or coordinate health care to all adult haemophilic patients through the Puerto Rico Pediatric Hemophilia Treatment Center. Information on the haemophilia care available in Latin American countries is scanty. The data available indicate that with a few exceptions, haemophilia care in this vast region is suboptimal. Apparently, early diagnosis is not common, there is lack of accessibility of services in most countries, comprehensive care is not the rule, safe high-purity AHF concentrates are used infrequently, and home care is used rarely. The main antihaemophilic products used are fresh frozen plasma and cryoprecipitate due to the high cost of modern antihaemophilic factor concentrates. The average per capita income of the main Latin American countries is about one-quarter of that of the USA and Canada. The existing economic situation of most Latin American countries would make it very difficult for them to purchase modern antihaemophilic products regularly and provide quality comprehensive care to their haemophilia patients, unless they make special efforts and get some type of external help. As a result of this study recommendations are made to improve the quality and accessibility of services to haemophilia patients in Latin America and other nonaffluent countries.
authors.affiliation: Hematology-Oncology Section, Department of Paediatrics, University of Puerto Rico, Medical Sciences Campus School of Medicine, San Juan, Puerto Rico 00936-5067, USA. psantiagoorcmnt7@upr.clu.edu
authors.forename: P J
authors.initials: PJ
authors.lastname: Santiago-Borrero
authors.forename: I
authors.initials: I
authors.lastname: Ortiz
authors.forename: E
authors.initials: E
authors.lastname: Rivera-Caragol
authors.forename: N I
authors.initials: NI
authors.lastname: Maldonado
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003029:Coagulants / Q000191:economics / Q000627:therapeutic use; D005169:Factor VIII / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006296:Health Services / Q000191:economics / Q000706:statistics & numerical data; D006467:Hemophilia A / Q000191:economics* / Q000628:therapy; D006801:Humans; D007843:Latin America; D011446:Prospective Studies; D011647:Puerto Rico; D011795:Surveys and Questionnaires
chemical_list: D003029:Coagulants; D005169:Factor VIII